Abstract: Nowadays, AIDS still remains as a worldwide pandemic and continues to cause many deaths which arise from HIV-1 virus. For nearly 35 years, drugs that target various steps of virus life cycle have been developed. HIV-1 integrase constitutes one of these steps which is essential for virus life cycle. Computer-aided drug design is being used in many drug development and drug improvement studies as also used in development of the first HIV-1 integrase inhibitor Raltegravir. In this study, 3 ligands which are already used as HIV-1 integrase inhibitors and 4 newly designed ligands were docked to catalytic core domain of HIV-1 integrase. Each ligand docked to three different conformations of protein. Prepared complexes (21 items) were carried out by 50 ns MD simulations and results were analyzed. Finally, the binding free energies of ligands were calculated. It was determined that designed ligands L01 and L03 gave favorable results. The questions about the ligands which have low docking scores in a conformation of protein could give better scores in another conformation of protein and if the MD simulations carry the different oriented and different localized ligands in same position at the end of simulation were answered.
INTRODUCTION

Human immunodeficiency virus (HIV) is a member of lentiviruses genus from retroviruses
family, which causes a worldwide pandemic of acquired immunodeficiency syndrome (AIDS). It was recently reported that there are about 35 million (33.2 million-34.0 million) people living with human immunodeficiency virus type 1 (HIV-1) at 2015, 1.5 million (1.4 million-1.7 million) deaths that related to AIDS, and 2.1 million (1.9 million -2.4 million) newly infected people [1] .
HIV-1 pol gen encodes three essential enzymes, namely reverse transcriptase (RT), integrase (IN), and protease (PR) which are essential for virus life cycle [2] . Because of the roles of these enzymes they attract most attention in HIV-1 drug discovery studies.
Although the first FDA-approved HIV-1 drug Zidovudine [3, 4] (AZT), was a nucleoside reverse-transcriptase inhibitor (NRTI) in the following years another drugs of different targets were discovered. Besides NRTIs, nucleotide reverse-transcriptase inhibitors (NtRTIs), non-nucleoside reverse-transcriptase inhibitors (NNRTIs) are discovered which also target RT enzyme. Other anti-HIV drug groups are as follows: Protease inhibitors (PIs), fusion inhibitors (FIs), co-receptor inhibitors (CRIs) and integrase inhibitors (INIs) [5, 6] .
However, instead of using single drugs, a combination of RT and PR drugs, named Highly Active Antiretroviral Therapy (HAART) is used to suppress viral replication of HIV-1 [7] [8] [9] .
HAART has an achievement on reducing disease progression, but it is also related to collateral problems like resistance of antivirals, toxicity and dosing which are preventing successful treatment of HIV [8, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . These shortfalls of HAART drugs' combinations point out the need for new drugs. Therefore, in this study, we tried to get some new inhibitors whose analogues showed good docking scores and interactions with IN in our previous work [20] . In contrast to many approved drugs which target RT and PR, only three IN inhibitors are currently approved as antiviral drugs. After approving Raltegravir [23] , and Dolutegravir (DLG: (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido [5, 6] pyrazino [2,6-b] [1, 3] oxazine-9-carboxamide) [24] for market distribution.
HIV-1 integrase is a 32 kDa protein consisting of 288 amino acids and is a polynucleotidyl Integrase mediates the insertion of viral DNA to host chromosomal DNA. It cuts a copy of double-stranded DNA of reverse transcribed viral RNA from the 3' ends and inserts into the host DNA. Integration occurs in two distinct steps. In the first step called 3' processing integrase cuts two or three nucleotides from the long terminal repeats (LTR) of vDNA at highly conserved CA bases which expose 3'-hydroxyl groups. Second step, involving insertion of processed vDNA to host DNA, is strand transfer reaction. IN catalyzes 3'-hydroxyl groups exposed from first step to attack host DNA from phosphate groups [25] .
Thus, these reactions also make IN a specific target because human body does not need such a process.
Due to solubility and inter-domain flexibility problems, full-length structure of integrase could not be solved yet. This issue also is one reason of later development of IN inhibitors.
However, individual structure of domains and combination of core domain with N-terminal domain [26] and C-terminal domain [27] have been solved by crystallography and nuclear magnetic resonance (NMR) techniques. Among these structures, only 1BL3 [28] and 2ITG [29] contain the flexible loop that consists of residues between 140-149. After identifying a crystal structure of catalytic core domain with a ligand (5CITEP: 1-(5-chloro-1H-indol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)) [30] , IN catches attention as a new target of antiviral drug studies. An advantage of targeting IN is that there is not any homologue enzyme of IN in human body. However, beside use of different sets of chemical molecule types for inhibition of integrase, only β-diketo acids and their bioisosteres are the approved inhibitors and some of them are in clinical trial [31] . Furthermore, in recent years the crystal structures of prototype foamy virus integrase (PFV IN) with viral DNA and also contain the integrase inhibitors RAL, EVG, and DLG have been reported [32, 33] . Notwithstanding the only 15% sequence similarity between HIV integrase and PFV integrase the structure of integrase with vDNA provide new perspectives for researchers to understand inhibitor interactions with receptor and also DNA and researchers used these structures as templates for modelling full-length HIV-1 integrase by computational tools [32] [33] [34] .
Drug development and improvement are expensive and time-consuming processes.
Computational methods such as docking, molecular dynamics, and free energy computations are widely used to help development of new drugs, understanding interactions of drugs with receptors and also reaction mechanisms taking place in inhibition. It is known that receptors are flexible in vivo and even though some docking programs allow flexible protein and ligand docking, but it is a time-consuming process and such a process also could be performed by molecular dynamics after docking process.
Therefore, this study also aspires to detail interactions of ligands with receptor in different conformations of protein and to define whether a docking program could mislead a researcher for obtaining best ligand. Namely, in general, a researcher uses docking program for one conformation of protein to dock a series of ligands, but this is only a snapshot of dynamic protein. A ligand could be an inappropriate candidate in a conformation of protein according to docking score and could be a good candidate in another conformation of protein. Also we want to define if the molecular dynamics studies carry these complexes; which different conformations of receptor have differently oriented ligands in it, to same point at (in terms of conformation of ligand and also ligand-receptor interactions) the end of simulation. Two such like studies have been performed by Brigo and co-workers [35, 36] . They have studied differences between wild and mutant type proteins containing 5CITEP as ligand without docking. The coordinates of studied structures are taken from cluster analyses' trajectories in one of these works [35] . In the second work [36] , they studied MD behaviors of protein which some diketo acid derivatives and also 5CITEP docked in. 
MATERIALS AND METHODS
Preparation of Used Protein Model
The crystallographic structure of CCD was obtained from the Protein Data Bank (www.rcsb.org) [38] with the code 1BL3.pdb. This structure contains A, B, and C chains.
We used chain C because it has 50-209 residues (others have missing residues) and one Mg atom in the catalytic site. It is known that integrase catalyzes strand transfer reaction when we have two metal atoms [39] . Therefore, second Mg atom was inserted to model by superimposing C chain of 1BL3.pdb with chain A of the recently solved crystal structure of PFV integrase with pdb code 4BE2 [40] . Superimposition showed that the E152 residue of 1BL3.pdb is in an inappropriate conformation which results in being far from second Mg atom. So it also replaced with E152 residue of 4BE2.pdb. All crystal water molecules were kept in simulation.
The model loaded to Xleap module of AMBER 12 [41] and hydrogen atoms were added automatically by module. Model was neutralized by adding Cl -ions and solvated with TIP3P [42] water model in a truncated octahedral box having at least 10 Å distance around the receptor and a distance of 0.4 Å between protein and solute. The Amber ff99SB force field was used for the protein.
Preparation of the ligands
The ligands were designed on the basis of structures those are previously studied such as folic acid, methotrexate, and designed compounds LGA and LGB [20] . Ligand optimizations were performed by Gaussian 09 [43] program in three steps. In the first step, all ligands were optimized with semi-empirical AM1 method, followed by B3LYP/6-31+(d,p) optimization and finally latest optimizations were carried out by HF/6-31G* level to produce partial charges of ligands with RESP. Antechamber and parmchk modules of ABMER package program was used to prepare ligands for Xleap program and to create additional force field files which contain missing parameters of any ligands. After docking studies, the RESP charges (Supp. Inf.) of each ligand were added in Xleap program by editing molecules.
Molecular Dynamics Studies of Receptor
The minimization of receptor carried out in three steps. In the first step, all the system without water was kept fixed to minimize water molecules. In the second step, water and H atoms of protein are taken free while protein and Mg atoms were kept fixed. In the first and second step, a force constant of 5.0 kcal mole
was used to restrain fixed atoms.
In final minimization, all the system was released free. Minimizations carried out as 1000 steps steepest descent method followed by 1000 steps conjugate gradient method.
Minimization and MD simulations were carried out with pmemd module of AMBER 12.
Minimized structure was used as starting point of MD simulation. Before production simulations, the system was heated to 300 K for 500 ps where protein except hydrogens and Mg atoms restrained with 1.0 kcal mole
force constant. Heating followed by a 500 ps equilibration simulation.
MD simulations were performed at 300 K temperature. Langevin thermostat with a collision frequency of 2 was used to maintain the temperature of system. The long-range electrostatic interactions were treated by the Particle Mesh Ewald (PME) protocol [44] with a 10 Å cut-off distance. To constrain bond lengths involving hydrogens, SHAKE [45] algorithm was applied. A time step of 2 fs and periodic boundary conditions were employed throughout simulation.
After 20 ns MD simulation of receptor cluster analyses were carried out by kclust tool of MMTSB Toolset [46] based on RMSD mode. Three different cluster sets of receptor were defined and best models of each clusters were used for docking, MD simulations of complexes and MM/PB(GB)SA calculations.
Docking Studies
All docking studies were carried out with AutoDock 4 [47] docking program and with the aid of MGL Tools [47] in preparing structures for docking and analyses of results.
Lamarckian Genetic Algorithm was used for docking with the settings of 150 individuals in a population, maximum energy evaluations of 2,500,000, maximum generations of 27,000 and 50 docking runs for each ligand. Autodock 4 scores docking of ligands by calculating their binding energies and the best scored conformations of ligands were selected for further studies.
Molecular Dynamics Studies of Complexes
Ligands having best scores for each conformation of receptor combined in Xleap program and also RESP charges of ligands were added. The way and conditions detailed in molecular dynamics studies of receptor followed for molecular dynamics studies of complexes for 50 ns.
MM/PB(GB)SA Studies
The binding free energies of ligands were calculated by MM/PBSA and MM/GBSA methods which implemented in AMBER 12 suite program as MMPBSA.py [37] . A schematic representation of thermodynamic cycle of method shown in Figure 2 . With an interval of 10 ps, 1000 snapshots were extracted from MD production trajectories. The binding free energy was computed from the free energy difference of the free ligand, free receptor and ligand-receptor complex as formulated below:
where Gcomplex, Greceptor, and Gligand are the free energy of complex, receptor and ligand molecules, respectively. These energy values are calculated using an average over the extracted snapshots taken from single MD trajectories. Each state can be estimated from molecular mechanics energy EMM, solvation free energy Gsol, and solute entropy S.
In Eq. (2), the terms ∆EMM, ∆Gsol, and -T∆S are dedicated to the changes of gas phase energy, solvation free energy, and the conformational entropy upon binding, respectively.
∆EMM is the sum of internal energy, ∆Eint, (bond, angle, and dihedral energies), electrostatic, ∆Eelectrostatic, and van der Waals energies, ∆Evdw which are computed from MD simulations. Solvation free energy, ∆Gsol, depends on polar and nonpolar contributions.
∆GPB/GB, is the electrostatic solvation free energy (polar contribution), and ∆GSA is the nonelectrostatic solvation energy (nonpolar contribution). The polar contribution is calculated from either PB or GB model. Dielectric constants for solute and solvent were set to 1 and 80, respectively. The nonpolar solvation energy, ∆GSA, was computed from the solvent accessible surface area (SASA) with a probe radius of 1.4 Å (Eq. (5)).
where γ is the surface tension constant and β is the offset constant. These values are set to 0.0072 kcal mol is represented as ribbon and basic style in Figure 4 . C1 constitutes 23.77% of 10,000 frames, where C2 and C3 constitute 61.51 % and 14.72 % of 10,000 frames, respectively.
As denoted from evaluation of RMSD plots there is not a major conversion in CCD structure. 
Docking Studies of Ligands
The approved HIV-1 integrase inhibitors RAL, EVG, and DTG and newly designed ligands
docked to CCD active site. The docking scores of ligands in C1, C2 and C3 structures are listed in Table 1 while hydrogen bonds seen between ligands and receptors and ligand atoms interacted with metals are shown in Table 2 . As an example of docking, the sites of three conformations of protein which L04 posed are depicted in Figure 5 and others were shown in Supporting Information (see Figure 3) . Differentiation of docking ligand to three conformations of protein structure obviously seen from figure. L04 is the best scored ligand in C1 while L01 has best score in both C1 and C3. All ligands seem to be best docked to C1 conformation of protein except EVG. Its docking score higher in C3 than in C1. also reported this issue in their study [19] . Besides, one must bear in mind that docking programs consider crystal structures containing ligand for developing program algorithms.
From Table 2 it has been seen that while all ligands interact with Mg atoms, some of ligands have four oxygen atoms in interaction with two Mg atoms. HIE67, GLU92, and ASN117 residues are found to create H bond with ligand atoms. The interactions of all ligands with protein residues at their docked sites are generally given in Table 3 . C1 conformation of protein has vdW interactions with all ligands. It is consistent with docking scores of ligands. HIE67O-H48 HIE67ND1-H45 ASP116OD1-H53 ASN117O-H62
HIE67ND1-H9 
ASN117O-H21 ASP64OD1-H20 ASN117O-H10, 
L04
Charge interactions: LEU68, HIE67 vdW: ASP64, CYS65, GLU69, GLY70, VAL72, GLU92, ASP116, GLU152, ASN155 π-sigma:THR66 Charge interactions: LEU68, LYS159 VAL72, ASP116
Charge interactions: PHE139 vdW: ASP64, CYS65, GLY140, PRO142, TYR143, GLU152
DTG
Charge interactions: HIE67, VAL72, LYS156 vdW: ASP64, CYS65, THR66, GLU92, ASP116, GLN148, ASN155
Charge interactions: HIE67, VAL72 vdW: ASP64, THR66, ASP116, TYR143, ASN155, LYS159
Charge interactions: CYS65 π-lone pair vdW: ASP64, THR66, ASP116, ASN117, GLY118, GLU152 EVG π- sigma: THR66  vdW: CYS65, HIE67, VAL72, GLU92, ASP116,  GLN148, GLU152, ASN155, LYS156, LYS159   vdW: CYS65, GLU92, GLY118, PRO142,  TYR143, GLU152   vdW: THR66, HIE67, GLY118, GLY140,  ILE141, PRO142, TYR143, GLU152, ASN155   RAL   Charge interactions: ILE141  vdW: THR66, HIE67, ASN117, SER119, TYR143,  ASN144, ASN155 π-π T-shaped:TYR143 Charge interactions: LEU68 vdW: ASP64, CYS65, THR66, GLU92, ASP116, ASN155
π-π t-shaped: HIE67 Charge interactions: HIE67, VAL72 vdW: CYS65, ALA91, ASN117 GLY118, THR143, ASN155
Molecular Dynamics Studies of the Complexes
From the RMSD plots of complexes versus time, it is seen that the proteins reached stable states ( Figure 6 ). In the plot of C1 complex of Dolutegravir, an ascension is seen at about 1.5-5 ns. MD movies of this complex showed the flexible loop between residues 185-198 are causing this rise. It is also seen from the RMSD plots of mentioned residues (not shown here). Figure 6 . The time evolution of RMSD values for backbone atoms of complexes, C1, C2, and C3 (L01 black, L02 red, L03 green, L04 blue, DTG cyan, EVG magenta, and RAL yellow).
All ligands seem to be in a stable state despite the high RMSD values of L02 and L03 in C1 ( Figure 7) . We also determined the ligands docked to different conformations of protein with diverse orientations and interactions did not resemble each other by MD simulations ( Figure 8 ). As an example, L01 docked to three different conformations of protein. Each docking orientation is different. And it could be seen that MD simulation did not put those three orientations of L01 to the same position ( Figure 8 ). We would like to point out that this is not an absolute result because an MD simulation of 50 ns (a sufficient time for an MD simulation) was performed in this study and it is not definite to know there will be a change or not by extending time. However, the clustering analyses performed for the 50 ns simulation show that the conformations of complexes are close to each other and so it is not necessary to depict the achieved clusters here. By the way, the images of structures having lowest energies illustrated here for each complex. (Table 4) . Table 5 . Binding free energies of ligands were calculated by Poisson-Boltzmann (PB) [37, 51] and Generalized-Born (GB) [37, 51] approaches. As the varying docking scores, interactions and orientations of ligands in different conformations of protein, binding free energies of ligands also differ from each other. In general, the scores of PB approach are at the lowest than scores of GB approach but in this study some of ligands gave greater PB scores than GB scores such as c1_L04, c2_L02, c2_L04, c2_dtg and c3_dtg/evg/ral. In the complexes which ligands having low binding energy, the electrostatic contributions seem to be lower and mainly the lower binding energy values are complying with this parameter. 
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